S
Sadao Kamidono
Researcher at Kobe University
Publications - 458
Citations - 9532
Sadao Kamidono is an academic researcher from Kobe University. The author has contributed to research in topics: Cancer & Cystectomy. The author has an hindex of 48, co-authored 458 publications receiving 9281 citations. Previous affiliations of Sadao Kamidono include Kawasaki Medical School & Jikei University School of Medicine.
Papers
More filters
Journal ArticleDOI
Conventional Versus Microdissection Testicular Sperm Extraction for Nonobstructive Azoospermia
Hiroshi Okada,Masaki Dobashi,Takafumi Yamazaki,Isao Hara,Masato Fujisawa,Soichi Arakawa,Sadao Kamidono +6 more
TL;DR: In nonobstructive cases, especially those of the Sertoli-cell-only syndrome, microdissection TESE can effectively retrieve spermatozoa and minimize the risk of complications.
Journal Article
Inactivation of the Retinoblastoma Gene in Human Bladder and Renal Cell Carcinomas
Jiro Ishikawa,Hong Ji Xu,Shi-Xue Hu,David W. Yandell,Sakan Maeda,Sadao Kamidono,William F. Benedict,Rei Takahashi +7 more
TL;DR: The results are the first to demonstrate the involvement of RB inactivation in the development of advanced primary bladder carcinoma and suggest that RB loss could have a role in certain renal cell carcinomas.
Journal ArticleDOI
Assessment of health-related quality of life in renal transplant and hemodialysis patients using the SF-36 health survey.
Masato Fujisawa,Yasuji Ichikawa,Kunihiko Yoshiya,Shuji Isotani,Akihiro Higuchi,Shunsuke Nagano,Soichi Arakawa,Hamami G,Osamu Matsumoto,Sadao Kamidono +9 more
TL;DR: The renal transplant patients' HQOL improved compared with that of the hemodialysis patients, and the most important factor affecting HQOL was the serum creatinine level at the time of testing with the SF-36 survey.
Journal ArticleDOI
Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer.
TL;DR: This study examined whether the serum levels of uPA and uPAR could be used as predictors of the progression and prognosis of prostate cancer.
Journal Article
A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Shigeji Matsubara,Yoshitaka Wada,Thomas A. Gardner,Thomas A. Gardner,Masayuki Egawa,Moon-Soo Park,Chia-Ling Hsieh,Haiyen E. Zhau,Chinghai Kao,Chinghai Kao,Sadao Kamidono,Jay Y. Gillenwater,Leland W. K. Chung +12 more
TL;DR: A cotargeting strategy using a conditional replication-competent adenovirus to target the growth of tumor cells and their associated osteoblasts appears to be more effective than systemic Ad-PSE-E1a in preclinical models of human prostate cancer skeletal metastasis.